Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)
Phase 4
Completed
- Conditions
- Angle-closure Glaucoma
- Interventions
- Registration Number
- NCT00762645
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study is to demonstrate that the Intraocular Pressure (IOP) lowering efficacy of Travoprost Ophthalmic Solution 0.004% is superior to that of Pilocarpine 1% in patients with chronic angle-closure glaucoma (CACG).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Age ≥ 18 years
- Chronic Angle Closure Glaucoma (CACG)
- 21-35 millimeters mercury mean intraocular pressure on Eligibility visit day at 9 AM
- Peripheral iridotomy performed ≥ 1 Month prior to the Screening visit
- Anterior chamber angle in which the trabecular meshwork is not visible for ≥180 degrees in gonioscopy without indentation
- Peripheral anterior synechiae (PAS)
Exclusion Criteria
- Traumatic damage of the anterior chamber angle
- History of ocular inflammation or surgery (except for iridotomy) ≤ 3 months
- Patients who cannot be safely discontinued from use of all ocular hypotensive medication(s) for 12 days to 14 weeks
- Visual Acuity ≥ 1.0
- Contact lenses wearer
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Travoprost 0.004% (Travatan) Travoprost 0.004% (Travatan) One drop in each eye, once daily at 9 AM Pilocarpine 1% Pilocarpine 1% One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
- Primary Outcome Measures
Name Time Method Mean Intraocular Pressure (IOP) 4PM at Week 12 Visit
- Secondary Outcome Measures
Name Time Method Number of Patients With Peripheral Anterior Synechiae (PAS) Week 12 Visit